Pacira BioSciences PCRX 深 沪
等待开盘 10-09 09:30:00 美东时间
36.29
+11.090
+44.01%
华盛通- 最 高36.33
- 今 开36.32
- 成交量 2530.53万股
- 最 低 36.27
- 昨 收 25.20
- 总市值 14.47亿
- 52周最高 36.33
- 市盈率 静 232.33
- 换手率 63.48%
- 52周最低 18.80
- 委 比 26.60%
- 总股本 3986.19万
- 历史最高 121.95
- 量 比 56.67
- 振 幅 0.24%
- 历史最低 6.51
- 每 手 1
- 风险率 1.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout
Viatris Inc. (NASDAQ:VTRS) announced Thursday that it agreed to acquire Pacira BioSciences Inc. (NASDAQ:PCRX) for $1.65 billion, strengthening its position in non-opioid pain management. Under the agreement, Viatris will pay $36.50 per share in cash for all outstanding Pacira shares. Viatris reporte...
今天 00:49
Needham Downgrades Pacira BioSciences to Hold
Needham analyst Serge Belanger downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Hold.
10-08 23:32
4 stocks to watch on Thursday: AVGO, PLTR, AMZN, and VTRS
Stock index futures slid on Thursday after oil prices rose as prospects for a peace agreement between Iran and the United States appeared difficult. Here are four stocks to watch on the day: Broadcom...
10-08 20:42
Viatris to buy Pacira BioSciences for $36.50/share in cash
Viatris (VTRS) and Pacira BioSciences (PCRX) said they entered into a definitive agreement under which Viatris will acquire all outstanding shares of Pacira for $36.50 per share in cash, representing ...
10-08 19:56
美股大行评级 | 潜在涨幅175.74%！美光科技获DA Davidson上调目标价至3000美元，维持"买入"评级
今日重点评级关注：DA Davidson：维持美光科技"买入"评级，目标价从2100美元升至3000美元；Leerink Partners：维持OmniAb"跑赢大市"评级，目标价从10美元升至12美元
10-08 12:30
Pacira taps Molteni to expand EXPAREL sales across EU and U.K
Pacira BioSciences (PCRX) signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K. Under the agreement, Pacira will receive an und...
10-05 20:32
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
Pacira BioSciences partners with Molteni Farmaceutici to expand access to EXPAREL, a non-opioid postsurgical pain management solution, across European markets. Molteni will distribute and commercialize EXPAREL in key European countries, starting with Italy, Germany, Austria, and Poland, with the first sales expected in 2027. This collaboration aligns with Pacira's 5x30 growth strategy and Molteni's expansion goals, aiming to address unmet needs i...
10-05 12:00
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32
Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.
09-23 18:33
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
